Skip to content
Medical Health Aged Care

ALERT – Whooping Cough Day Sat 8 Nov – Canberra Immunisation clinic and call for national approach to lift uptake of vaccinations in pregnancy

Immunisation Foundation of Australia < 1 mins read

This weekend, Canberra will be the centre of a national push to help lift the rate of vaccinations in pregnancy.

To mark Whooping Cough Day (8 November), the Immunisation Foundation of Australia, founded by mother Catherine Hughes AM, who lost her four-week-old son Riley to whooping cough, will host a pop-up vaccination clinic at the Canberra Pregnancy, Babies & Children’s Expo (Saturday 8 and Sunday 9 November).

The clinic will offer information on recommended vaccinations in pregnancy and the opportunity for eligible expectant mums to receive vaccinations.

The clinic coincides with the launch of a new national Maternal Immunisation in Australia whitepaper which highlights a critical gap in Australia's national immunisation approach.  Whilst we have national targets for childhood immunisation, none exist for maternal vaccination.

Experts say national maternal immunisation targets would help ensure every expectant mother in Australia receives consistent information and easy access to vaccination, no matter where she lives or how she receives care.

This is a strong local story with national significance and an important public health message.

Key vision opportunities:

  • Catherine Hughes speaking with expectant parents at the Canberra Expo
  • Pregnant women receiving vaccinations on-site
  • Families engaging with health experts at the Immunisation Foundation of Australia stall

For further information, to arrange an interview with Catherine on-site or coordinate filming opportunities at the Expo on Saturday 8 November please contact: 

Nicki Sambuco at [email protected] or on +61 (0) 452 446 084

Chloe Danvers at [email protected] or on +61 (0) 466 626 429

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.